India warns drugmakers against direct or surrogate weight-loss drug and obesity ads

Core Viewpoint - India's drug regulator has issued a warning to pharmaceutical companies against direct or indirect advertising of weight-loss medications, emphasizing that misleading promotions could lead to regulatory action [1]. Regulatory Environment - The Central Drugs Standard Control Organization (CDSCO) has reiterated existing drug rules that prohibit advertising prescription-only medicines to the public [1]. - Any promotional activities that exaggerate therapeutic efficacy or induce demand for drug therapy may be considered misleading marketing practices [1]. Market Dynamics - Global drugmakers Eli Lilly and Novo Nordisk, which launched obesity drugs in India last year, are actively trying to establish a strong presence in the domestic market [1]. - Both companies have increased outreach to healthcare professionals and have engaged in aggressive marketing campaigns to raise awareness about obesity as a disease [1]. Future Projections - India is projected to have the world's second-largest overweight or obese population by 2050, according to global health estimates [1]. - Domestic drugmakers are preparing to introduce cheaper versions of Novo Nordisk's obesity drug following the expiration of its patent in March [1]. Public Health Considerations - The advisory emphasizes that promotions of pharmaceutical therapies should not undermine public health initiatives aimed at preventive healthcare measures [1].